Profile data is unavailable for this security.
About the company
Avadel Pharmaceuticals plc is a biopharmaceutical company. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
- Revenue in USD (TTM)55.02m
- Net income in USD-30.20m
- LocationAvadel Pharmaceuticals PLCBlock 10-1 Blanchardstown Corporate ParkBallycoolinDUBLIN 15IrelandIRL
- Phone+353 14851200
- Fax+353 15261077